Mylan India Concluded 2019 with Seven Accolades

2019 was especially significant as Mylan in India ended the year with seven awards from several industry bodies; a testament to our efforts.

Mylan was felicitated with the Express Pharma Excellence Award during early 2019 for outstanding performance in exports. This was followed by the 'Platinum Pledge' status granted to Mylan at the USAID event in May for its contribution and efforts in expanding access to quality healthcare and medicines towards Tuberculosis (TB) in India through several interventions.

The winning streak continued with AWACS Marketing Excellence Awards in September. 'MyHepAll' won a silver and was a close 1st runner-up for 'Brand of the Year in Acute Category'; in the same category AmBisome®, competed with over 15 contestant brands, across multiple therapeutic categories, to win a bronze. In the 'chronic diseases brand of the year' category, 'HepBest', was recognized as the 2nd runner-up.

In November, the 'HepBuzz App' emerged as the winner in 'Leveraging Technology for Use of Mobile Application' for innovation in healthcare at the 2019 Wolters Kluwer Digital India Health Innovation Awards which focused on honoring organizations that have adopted digital tools and technology in redefining healthcare delivery.

The year concluded with a gold at the Marcom Awards for a mobile application with 24/7 support services to educate parents about atopic dermatitis and help them to track and manage their child's condition. The app also provides aid to healthcare practitioners with updated information about the disease.